Nuvation Bio Inc.

Nuvation Bio Inc. (Nasdaq: NUVB) is a clinical-stage biopharmaceutical company focused on oncology that became publicly listed through its business combination with Panacea Acquisition Corp. II, a blank-check company sponsored by Panacea Acquisition Holdings II LLC that completed its IPO in 2021. Founded by veteran oncology entrepreneur David Hung, Nuvation Bio is advancing a pipeline of differentiated cancer therapies targeting multiple tumor types. The company's May 2023 Form 8-K filing reflects its ongoing post-merger public reporting obligations in the biotechnology sector. For comprehensive data on NUVB and the broader SPAC universe, sign up for full access at SpacDesk.